385 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Venturi Wealth Management LLC

Venturi Wealth Management LLC acquired a new stake in United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 385 shares of the biotechnology company’s stock, valued at approximately $136,000.

Other hedge funds have also recently modified their holdings of the company. Newbridge Financial Services Group Inc. purchased a new position in shares of United Therapeutics in the fourth quarter valued at about $25,000. Brooklyn Investment Group purchased a new position in shares of United Therapeutics in the third quarter valued at about $33,000. Capital Performance Advisors LLP purchased a new position in shares of United Therapeutics in the third quarter valued at about $82,000. MassMutual Private Wealth & Trust FSB increased its position in shares of United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares during the period. Finally, Values First Advisors Inc. purchased a new position in shares of United Therapeutics in the third quarter valued at about $90,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on UTHR shares. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 16th. The Goldman Sachs Group lifted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. HC Wainwright lifted their target price on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. UBS Group lifted their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Finally, LADENBURG THALM/SH SH lifted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $388.25.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $348.06, for a total value of $3,480,600.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $896,950.62. This represents a 79.51 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Louis W. Sullivan sold 26,209 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the transaction, the director now owns 5,051 shares in the company, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 124,164 shares of company stock valued at $45,398,793 over the last quarter. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $361.10 on Friday. United Therapeutics Co. has a one year low of $214.75 and a one year high of $417.82. The company’s 50-day simple moving average is $362.68 and its 200 day simple moving average is $360.45. The firm has a market capitalization of $16.12 billion, a P/E ratio of 15.86, a PEG ratio of 0.97 and a beta of 0.57.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.